New drug combo aims to stop brain lymphoma from returning
NCT ID NCT04627753
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a two-year maintenance treatment with lenalidomide and rituximab can prevent relapse in patients with primary central nervous system lymphoma who have responded to initial chemotherapy but are not eligible for a stem cell transplant. The study will enroll 30 participants and track how long they live without the cancer progressing. The goal is to improve survival in a group that currently has very poor outcomes after relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenalidomide and rituximab (drugs)
- What this could lead to
- If successful, this maintenance therapy could help prevent relapse and extend survival for patients with primary CNS lymphoma who cannot undergo a stem cell transplant.
- What could go wrong
- This is a small, early-phase study (30 participants) with no control group. The drugs may cause side effects, and it is not yet known if they will meaningfully improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CNS LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Samsung Medical Center
RECRUITINGSeoul, 135710, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.